Want to see CSLLY full AI Analyst Report?
CSLLY Stock Chart & Stats
$58.43
$0.39(0.44%)
At close: 4:00 PM EST
$58.43
$0.39(0.44%)
Day’s Range― - ―
52-Week Range$16.48 - $44.25
Previous CloseN/A
Volume10.38K
Average Volume (3M)1.91K
Market Cap
$38.31B
Enterprise Value$47.57B
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.57B
Price to Earnings (P/E)26.8
Beta0.33
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.12%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,915,648,000
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio7.66
Price to Book (P/B)7.93
Price to Sales (P/S)9.94
P/FCF Ratio60.28
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue3.06
Enterprise Value/Gross Profit6.29
Enterprise Value/Ebitda9.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Generation & Capital ReturnsConsistent operating cash flow and active buybacks show durable free cash generation and disciplined capital allocation. Reduced leverage (~2x) improves financial flexibility to fund R&D, acquisitions, and dividends while supporting resilience through industry cycles over the next 2–6 months.
Strong Underlying Profitability And MarginsHigh gross and net margins reflect pricing power and manufacturing scale in plasma-derived and specialty biologics. Robust EBIT/EBITDA margins indicate efficient operations, supporting sustainable cash flow generation and reinvestment capacity even if near-term revenue growth moderates.
Vertical Plasma Franchise & Specialty LaunchesA vertically integrated plasma network plus successful specialty launches and differentiated vaccines create durable competitive advantages: proprietary supply, clinical differentiation, and diversified revenue streams, underpinning structural growth and margin resilience beyond short-term seasonal swings.
Bears Say
Large Impairments & Restructuring CostsMaterial noncash write-downs and substantial restructuring charges create multi-quarter earnings volatility and reduce reported equity. These impairments signal asset underperformance and, together with large one-off costs, constrain near-term capital allocation and complicate comparability of profitability metrics.
Immunoglobulin Franchise PressureReimbursement and contracting headwinds in the high-margin Ig franchise can persist structurally, weakening volumes and pricing. Given Ig's outsized contribution to revenue, sustained policy or payer pressure could materially restrain top-line recovery and long-term margin upside.
Generics & Loss‑of‑exclusivity Risks In Iron/renalGeneric entrants and impending loss of exclusivity for key iron therapies structurally erode pricing and volumes in the iron franchise. This secular decline reduces a previously stable revenue stream and pressures segment margins and cash flows across the next 2–6 months.
CSL News
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $16.48 and its highest was $44.25 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $38.31B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 18, 2026 which is in 21 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 10, 2026. The company reported $0.208 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.319 which represents an annual dividend yield of 3.12%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 1,915,648,000 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $0.208 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.342%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CSLLY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
3.12%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors